Keros Therapeutics Inc — Balance Sheet (NASDAQ:KROS) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Total assets 269.44 M255.25 M306.78 M370.02 M615.89 M Total liabilities 7.72 M12.08 M29.36 M37.81 M44.33 M Total equity 261.72 M243.17 M277.42 M332.21 M571.55 M Total liabilities & shareholders' equities 269.44 M255.25 M306.78 M370.02 M615.89 M Total debt ————— Net debt —————

Haberler

Keros Therapeutics eski Lyell CFO’sunu yönetim kuruluna aldı

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?

SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD

Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?

Is KROS' KER-065 the Next Breakthrough in DMD Space?

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease

Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia

Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?